Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Neuroendocrine carcinoma of the skin (Merkel cell)
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
Embolization Therapy with or without Chemotherapy in Controlling Liver Metastases in Patients with Neuroendocrine Tumor Metastases to the Liver That Cannot Be Removed by Surgery
Status: Active
Phase: Phase III
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: UPCC01215, NCI-2016-00610, NCT02724540
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab with or without Cellular Adoptive Immunotherapy in Treating Patients with Metastatic Merkel Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9245, NCI-2014-02462, FHCRC 9245, NCT02584829
Sapanisertib in Treating Patients with Recurrent or Metastatic Merkel Cell Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-223, NCI-2016-00695, NCT02514824
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 100070-003, NCI-2014-01995, 2014-000445-79, NCT02155647
Pembrolizumab in Treating Patients with Advanced Merkel Cell Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-09, NCI-2014-00848, MK-3475, NCT02267603
QUILT-3.009: Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: QUILT-3.009, NCI-2015-01343, MCC-001, NCT02465957
Ramucirumab and Somatostatin Analog Therapy in Treating Patients with Locally Advanced or Metastatic Carcinoid Tumor That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-072, NCI-2016-00941, NCT02795858
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TTI-621-02, NCI-2016-01486, NCT02890368
Veliparib, Capecitabine, and Temozolomide in Treating Patients with Advanced, Metastatic, and Recurrent Neuroendocrine Tumor That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 19 and over
Trial IDs: VICC GI 14134, NCI-2016-01044, NCT02831179
Cabozantinib-S-Malate in Treating Patients with Recurrent or Metastatic Merkel Cell Carcinoma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 13-490, NCI-2014-00941, NCT02036476
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Start Over